Changes in the secretory profile of NSCLC-associated fibroblasts after ablative radiotherapy: Potential impact on angiogenesis and tumor growth

Translational Oncology

Volumn 6, Issue 1, 2013, Pages 66-74

  Hellevik, Turid ^a   Pettersen, Ingvild ^b   Berg, Vivian ^b   Bruun, Jack ^b   Bartnes, Kristian ^a   Busund, Lill Tove ^a,b   Chalmers, Anthony ^c   Bremnes, Roy ^a,b   Martinez Zubiaurre, Iñigo ^b  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN; CONNECTIVE TISSUE GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GROWTH ARREST SPECIFIC PROTEIN 6; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE MIGRATION INHIBITION FACTOR; PIGMENT EPITHELIUM DERIVED FACTOR; PLATELET DERIVED GROWTH FACTOR; SCATTER FACTOR; SOMATOMEDIN B; STROMAL CELL DERIVED FACTOR 1; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CANCER ASSOCIATED FIBROBLAST; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; FIBROBLAST; HUMAN; HUMAN CELL; INFLAMMATION; IONIZING RADIATION; IRRADIATION; LUNG NON SMALL CELL CANCER; PROTEIN EXPRESSION; PROTEOMICS; RADIATION DOSE; TANDEM MASS SPECTROMETRY; TUMOR GROWTH;

EID: 84874710060     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.12349     Document Type: Article

References (62)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, and Parkin DM (2010). Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127, 2893-2917.
2. Powell JW, Dexter E, Scalzetti EM, and Bogart JA (2009). Treatment advances for medically inoperable non-small-cell lung cancer: emphasis on prospective trials. Lancet Oncol 10, 885-894.
3. Kavanagh BD, Miften M, and Rabinovitch RA (2011). Advances in treatment techniques: stereotactic body radiation therapy and the spread of hypofractionation. Cancer J 17, 177-181.
4. Heinzerling JH, Kavanagh B, and Timmerman RD (2011). Stereotactic ablative radiation therapy for primary lung tumors. Cancer J 17, 28-32.
5. Lanni TB Jr, Grills IS, Kestin LL, and Robertson JM (2011). Stereotactic radiotherapy reduces treatment cost while improving overall survival and local control over standard fractionated radiation therapy for medically inoperable non-small-cell lung cancer. Am J Clin Oncol 34, 494-498.
6. Palma D and Senan S (2011). Stereotactic radiation therapy: changing treatment paradigms for stage I nonsmall cell lung cancer. Curr Opin Oncol 23, 133-139.
7. Senan S, Palma DA, and Lagerwaard FJ (2011). Stereotactic ablative radiotherapy for stage I NSCLC: recent advances and controversies. J Thorac Dis 3, 189-196.
8. Hanahan D and Weinberg RA (2000). The hallmarks of cancer. Cell 100, 57-70.
9. Bissell MJ and Radisky D (2001). Putting tumours in context. Nat Rev Cancer 1, 46-54.
10. Hanahan D and Coussens LM (2012). Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 21, 309-322.
11. Hanahan D and Weinberg RA (2011). Hallmarks of cancer: the next generation. Cell 144, 646-674.
12. Brown JM and Koong AC (2008). High-dose single-fraction radiotherapy: exploiting a new biology? Int J Radiat Oncol Biol Phys 71, 324-325.
13. Barcellos-Hoff MH, Park C, and Wright EG (2005). Radiation and the microenvironment-tumorigenesis and therapy. Nat Rev Cancer 5, 867-875.
14. Golden EB, Pellicciotta I, Demaria S, Barcellos-Hoff MH, and Formenti SC (2012). The convergence of radiation and immunogenic cell death signaling pathways. Front Oncol 2, 88.
15. Schaue D, Xie MW, Ratikan JA, and McBride WH (2012). Regulatory T cells in radiotherapeutic responses. Front Oncol 2, 90.
16. Lugade AA, Moran JP, Gerber SA, Rose RC, Frelinger JG, and Lord EM (2005). Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 174, 7516-7523.
17. + T cells via dendritic cell activation. J Immunol 189, 558-566.
18. + T cells: changing strategies for cancer treatment. Blood 114, 589-595.
19. Paris F, Fuks Z, Kang A, Capodieci P, Juan G, Ehleiter D, Haimovitz-Friedman A, Cordon-Cardo C, and Kolesnick R (2001). Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293, 293-297.
20. Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, Fuks Z, and Kolesnick R (2003). Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300, 1155-1159.
21. Bhowmick NA, Neilson EG, and Moses HL (2004). Stromal fibroblasts in cancer initiation and progression. Nature 432, 332-337.
22. Orimo A and Weinberg RA (2006). Stromal fibroblasts in cancer: a novel tumor-promoting cell type. Cell Cycle 5, 1597-1601.
23. Kalluri R and Zeisberg M (2006). Fibroblasts in cancer. Nat Rev Cancer 6, 392-401.
24. Bremnes RM, Donnem T, Al-Saad S, Al-Shibli K, Andersen S, Sirera R, Camps C, Marinez I, and Busund LT (2011). The role of tumor stroma in cancer progression and prognosis: emphasis on carcinoma-associated fibroblasts and non-small cell lung cancer. J Thorac Oncol 6, 209-217.
25. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, Carey VJ, Richardson AL, and Weinberg RA (2005). Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348.
26. Ksiazkiewicz M, Gottfried E, Kreutz M, Mack M, Hofstaedter F, and Kunz-Schughart LA (2010). Importance of CCL2-CCR2A/2B signaling for monocyte migration into spheroids of breast cancer-derived fibroblasts. Immunobiology 215, 737-747.
27. Gaggioli C, Hooper S, Hidalgo-Carcedo C, Grosse R, Marshall JF, Harrington K, and Sahai E (2007). Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 9, 1392-1400.
28. Duda DG, Duyverman AM, Kohno M, Snuderl M, Steller EJ, Fukumura D, and Jain RK (2010). Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci USA 107, 21677-21682.
29. Barcellos-Hoff MH and Ravani SA (2000). Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res 60, 1254-1260.
30. Liu D and Hornsby PJ (2007). Senescent human fibroblasts increase the early growth of xenograft tumors via matrix metalloproteinase secretion. Cancer Res 67, 3117-3126.
31. Rodier F, Coppe JP, Patil CK, Hoeijmakers WA, Munoz DP, Raza SR, Freund A, Campeau E, Davalos AR, and Campisi J (2009). Persistent DNA damage signalling triggers senescence-associated inflammatory cytokine secretion. Nat Cell Biol 11, 973-979.
32. Wang W, Li Q, Yamada T, Matsumoto K, Matsumoto I, Oda M, Watanabe G, Kayano Y, Nishioka Y, Sone S, et al. (2009). Crosstalk to stromal fibroblasts induces resistance of lung cancer to epidermal growth factor receptor tyrosine kinase inhibitors. Clin Cancer Res 15, 6630-6638.
33. Mueller KL, Madden JM, Zoratti GL, Kuperwasser C, List K, and Boerner JL (2012). Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Breast Cancer Res 14, R104.
34. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian ZR, Du J, Davis A, MongareMM, Gould J, Frederick DT, et al. (2012). Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 487, 500-504.
35. Liu D and Hornsby PJ (2007). Fibroblast stimulation of blood vessel development and cancer cell invasion in a subrenal capsule xenograft model: stressinduced premature senescence does not increase effect. Neoplasia 9, 418-426.
36. Hellevik T, Pettersen I, Berg V, Winberg JO, Moe BT, Bartnes K, Paulssen RH, Busund LT, Bremnes R, Chalmers A, et al. (2012). Cancer-associated fibroblasts from human NSCLC survive ablative doses of radiation but their invasive capacity is reduced. Radiat Oncol 7, 59.
37. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, and Rettig WJ (1999). Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 274, 36505-36512.
38. de Jager W, te Velthuis H, Prakken BJ, Kuis W, and Rijkers GT (2003). Simultaneous detection of 15 human cytokines in a single sample of stimulated peripheral blood mononuclear cells. Clin Diagn Lab Immunol 10, 133-139.
39. Khan SS, Smith MS, Reda D, Suffredini AF, and McCoy JP Jr (2004). Multiplex bead array assays for detection of soluble cytokines: comparisons of sensitivity and quantitative values among kits from multiple manufacturers. Cytometry B Clin Cytom 61, 35-39.
40. Shevchenko A, Jensen ON, Podtelejnikov AV, Sagliocco F, Wilm M, Vorm O, Mortensen P, Boucherie H, and Mann M (1996). Linking genome and proteome by mass spectrometry: large-scale identification of yeast proteins from two dimensional gels. Proc Natl Acad Sci USA 93, 14440-14445.
41. Ishihama Y, Oda Y, Tabata T, Sato T, Nagasu T, Rappsilber J, and Mann M (2005). Exponentially modified protein abundance index (emPAI) for estimation of absolute protein amount in proteomics by the number of sequenced peptides per protein. Mol Cell Proteomics 4, 1265-1272.
42. Xing JZ, Zhu L, Gabos S, and Xie L (2006). Microelectronic cell sensor assay for detection of cytotoxicity and prediction of acute toxicity. Toxicol In Vitro 20, 995-1004.
43. Atienza JM, Yu N, Kirstein SL, Xi B, Wang X, Xu X, and Abassi YA (2006). Dynamic and label-free cell-based assays using the real-time cell electronic sensing system. Assay Drug Dev Technol 4, 597-607.
44. Abassi YA, Xi B, Zhang W, Ye P, Kirstein SL, Gaylord MR, Feinstein SC, Wang X, and Xu X (2009). Kinetic cell-based morphological screening: prediction of mechanism of compound action and off-target effects. Chem Biol 16, 712-723.
45. Eisenberg MC, Kim Y, Li R, Ackerman WE, Kniss DA, and Friedman A (2011). Mechanistic modeling of the effects of myoferlin on tumor cell invasion. Proc Natl Acad Sci USA 108, 20078-20083.
46. Arnaoutova I and Kleinman HK (2010). In vitro angiogenesis: endothelial cell tube formation on gelled basement membrane extract. Nat Protoc 5, 628-635.
47. West MD, Pereira-Smith OM, and Smith JR (1989). Replicative senescence of human skin fibroblasts correlates with a loss of regulation and overexpression of collagenase activity. Exp Cell Res 184, 138-147.
48. Suzuki M and Boothman DA (2008). Stress-induced premature senescence (SIPS)-influence of SIPS on radiotherapy. J Radiat Res 49, 105-112.
49. Lee AC, Fenster BE, Ito H, Takeda K, Bae NS, Hirai T, Yu ZX, Ferrans VJ, Howard BH, and Finkel T (1999). Ras proteins induce senescence by altering the intracellular levels of reactive oxygen species. J Biol Chem 274, 7936-7940.
50. Mishra P, Banerjee D, and Ben-Baruch A (2011). Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy. J Leukoc Biol 89, 31-39.
51. Erez N, Truitt M, Olson P, Arron ST, and Hanahan D (2010). Cancerassociated fibroblasts are activated in incipient neoplasia to orchestrate tumorpromoting inflammation in an NF-κB-dependent manner. Cancer Cell 17, 135-147.
52. Kuhlmann UC, Chwieralski CE, Reinhold D, Welte T, and Buhling F (2009). Radiation-induced matrix production of lung fibroblasts is regulated by interleukin-8. Int J Radiat Biol 85, 138-143.
53. Ohuchida K, Mizumoto K, Murakami M, Qian LW, Sato N, Nagai E, Matsumoto K, Nakamura T, and Tanaka M (2004). Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res 64, 3215-3222.
54. Olson OC and Joyce JA (2012). Microenvironment-mediated resistance to anticancer therapies. Cell Res [E-pub ahead of print].
55. Fuks Z, Persaud RS, Alfieri A, McLoughlin M, Ehleiter D, Schwartz JL, Seddon AP, Cordon-Cardo C, and Haimovitz-Friedman A (1994). Basic fibroblast growth factor protects endothelial cells against radiation-induced programmed cell death in vitro and in vivo. Cancer Res 54, 2582-2590.
56. Rades D, Setter C, Dahl O, Schild SE, and Noack F (2012). Fibroblast growth factor 2-a predictor of outcome for patients irradiated for stage II-III nonsmall-cell lung cancer. Int J Radiat Oncol Biol Phys 82, 442-447.
57. Wilson TR, Fridlyand J, Yan Y, Penuel E, Burton L, Chan E, Peng J, Lin E, Wang Y, Sosman J, et al. (2012). Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature 487, 505-509.
58. Takeuchi S, Wang W, Li Q, Yamada T, Kita K, Donev IS, Nakamura T, Matsumoto K, Shimizu E, Nishioka Y, et al. (2012). Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Am J Pathol 181, 1034-1043.
59. Rendon BE, Willer SS, Zundel W, and Mitchell RA (2009). Mechanisms of macrophage migration inhibitory factor (MIF)-dependent tumor microenvironmental adaptation. Exp Mol Pathol 86, 180-185.
60. Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, Pestell TG, Howell A, Sneddon S, Pestell RG, Martinez-Outschoorn U, Lisanti MP, et al. (2012). CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 11, 2272-2284.
61. Thijssen VL, Brandwijk RJ, Dings RP, and Griffioen AW (2004). Angiogenesis gene expression profiling in xenograft models to study cellular interactions. Exp Cell Res 299, 286-293.
62. Tseng D, Vasquez-Medrano DA, and Brown JM (2011). Targeting SDF-1/ CXCR4 to inhibit tumour vasculature for treatment of glioblastomas. Br J Cancer 104, 1805-1809.